Takeda Pharmaceutical Company Limited (TKPHF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Christophe Weber.
TKPHF hat IPO-Datum 2008-06-25, 49,281 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $54.53B.
Takeda Pharmaceutical Company Limited is a global pharmaceutical company headquartered in Tokyo, Japan, with operations across Japan, the United States, Europe, and other international markets. Founded in 1781, the company engages in the research, development, manufacture, and marketing of pharmaceutical products across five core therapeutic areas: gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Takeda markets numerous branded pharmaceutical products including Entyvio, Velcade, Adcetris, and Takhzyro, among others, and maintains an extensive network of collaborations, licensing agreements, and strategic alliances with leading research institutions and biotechnology companies worldwide to support its innovation pipeline.
